Mantle cell lymphoma (MCL) is one of the most aggressive B-cell non-Hodgkin lymphomas with a median survival of approximately five years. Currently, there is no curative therapy available for refractory MCL because of relapse from therapy-resistant tumor cells. The NF-kB and mTOR pathways are constitutively active in refractory MCL leading to increased proliferation and survival. Targeting these pathways is an ideal strategy to improve therapy for refractory MCL. Therefore, we investigated the in vitro and in vivo antilymphoma activity and associated molecular mechanism of action of a novel compound, 13-197, a quinoxaline analog that specifically perturbs IkB kinase (IKK) b, a key regulator of the NF-kB pathway. 13-197 decreased the proliferation and induced apoptosis in MCL cells including therapy-resistant cells compared with control cells. Furthermore, we observed downregulation of IkBa phosphorylation and inhibition of NF-kB nuclear translocation by 13-197 in MCL cells. In addition, NF-kB-regulated genes such as cyclin D1, Bcl-XL, and Mcl-1 were downregulated in 13-197-treated cells. In addition, 13-197 inhibited the phosphorylation of S6K and 4E-BP1, the downstream molecules of mTOR pathway that are also activated in refractory MCL. Further, 13-197 reduced the tumor burden in vivo in the kidney, liver, and lungs of therapy-resistant MCL-bearing nonobese diabetic severe-combined immunodeficient (NOD/SCID) mice compared with vehicle-treated mice; indeed, 13-197 significantly increased the survival of MCL-transplanted mice. Together, results suggest that 13-197 as a single agent disrupts the NF-kB and mTOR pathways leading to suppression of proliferation and increased apoptosis in malignant MCL cells including reduction in tumor burden in mice.
Introduction
Mantle cell lymphoma (MCL) is one of the most aggressive B-cell malignancies with a median survival of approximately 5 years due to relapse from therapy-resistant tumor cells (1) (2) (3) (4) (5) . Despite availability of new agents to combine with high-dose therapy followed by stem cell transplantation, the rate of disease-free survival in MCL is disappointing (5) (6) (7) (8) . Therefore, identification of key cellular/molecular pathways that can be targeted to refractory state of MCL and the development of an effective therapeutic strategy for targeting those pathways is needed.
MCL has a characteristic chromosomal translocation t(11;14)(q13;q32), a hallmark of this disease that results in cyclin D1 overexpression, which is believed to contribute to deregulated proliferation in MCL (9) . Although it is widely accepted that cyclin D1 has an important role in the pathogenesis of MCL, accumulating evidence suggests that MCL often has defects in many other cellular processes, such as those involved in cell-cycle regulation, apoptosis, and DNA repair. MCL is known to be resistant to apoptosis with existing therapy. Recent studies have revealed a number of biochemical defects that may contribute to its relatively high resistance to apoptosis due to overexpression of several antiapoptotic proteins. Several lines of evidence indicate that the NF-kB pathway is constitutively active in MCL and leads to the overexpression of several antiapoptotic molecules (9) (10) (11) (12) (13) (14) (15) . In addition, gene expression analyses of samples from patients of MCL and therapy-resistant MCL cells derived from different tissue sites have frequently shown high expression of NFkB target genes (12, 16, 17) . Consequently, inhibition of this constitutive activation of NF-kB has been shown to elicit cell-cycle arrest and cell death in MCL cells (10, (13) (14) (15) 18) . Strong evidence implicating the NF-kB pathway in the onset and progression of MCL has made it an attractive target for therapeutic intervention. Aberrant cellular signaling, such as in the phosphoinositide 3-kinase (PI3K)/ mTOR pathway, may also contribute to the chemoresistance of MCL (19, 20) . Targeting these pathways can be a novel approach for developing a new therapeutic strategy for improved treatment of refractory MCL.
IkB kinase b (IKKb) is a key upstream kinase in the NFkB pathway that is activated by immune and inflammatory responses regulating cell growth and survival in the pathogenesis of various solid and hematologic malignancies (21) . In general, NF-kB is transcriptionally inactive in the cytoplasm of most cells through interaction with its cytoplasmic inhibitor protein called IkBa. On activation, the IKKb becomes phosphorylated and active. Activated IKKb phosphorylates NF-kB-bound IkBa and targets it for polyubiquitination and proteasome-mediated degradation (21) (22) (23) . As a consequence, free NF-kB dimers are further activated through posttranslational modifications and translocate to the nucleus, resulting in transcriptional activation of several hundred survival-, proliferation-, and apoptosis-associated genes (21) (22) (23) (24) (25) . In addition, the IKKb is known to result in the activation of tuberous sclerosis 1 (TSC1). The phosphorylation-mediated suppression of TSC1 results in the activation of the mTOR pathway (26, 27) . Together, these data suggest that IKKb is a key kinase and, on activation, it regulates transcription of genes through the NF-kB pathway and translation of the gene products through the mTOR pathway. Recently, IKKb has made an attractive target for therapeutic development (28) (29) (30) . Although several IKKb inhibitors have been used for the treatment of diseases in preclinical studies, so far, none have received FDA approval (31) . One possible reason for this is the observed toxicity (ML-120B and TPCA1) in preclinical models (32, 33) . Therefore, the development of IKKb inhibitors without toxicity in clinics is needed.
Compounds containing the quinoxaline core are found in a number of natural products as validated hits from high-throughput screens, clinical candidates, and drugs on the market (34) . Synthesis and screening of a focused library of quinoxaline compounds led to a well-defined structure-activity relationship and the identification of a quinoxaline urea analogue that inhibited growth of cancer cells with low micromolar potency (35, 36) . In addition, recent studies by us suggest that the quinoxaline urea analog 13-197 inhibits the constitutively active form of IKKb which is an emerging target for therapeutic development (28) (29) (30) . In cell-based NF-kB-driven dual luciferase assay, the potency of 13-197 is comparable with the reported NF-kB inhibitors, parthenolide, curcumin and noscapine (37) . Considering that IKKb and the NF-kB pathway are constitutively active in the therapy-resistant MCL, we speculated that 13-197 might be a therapeutic option for refractory MCL.
The effect of this novel inhibitor and its molecular mechanism(s) against MCL have not been described. Therefore, we evaluated the efficacy and potency of as a single agent targeting NF-kB and mTOR pathways in MCL and therapy-resistant MCL cell lines. We found that 13-197-treated cells showed inhibition of IkB phosphorylation and phosphorylation of S6K and 4E-BP1 which are downstream of IKKb in the NF-kB and mTOR pathways, respectively. This resulted in significant suppression of proliferation and increased apoptosis in MCL cells including therapy-resistant cells, as well as reduction of tumor burden in mice. Our data strongly supports 13-197 as a novel and potential therapeutic agent against malignant MCL to be further explored to take to clinic.
Materials and Methods

Cell lines and maintenance
The MCL cell line Granta 519 was obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Germany) and Rec-1 and Mino were obtained from the American Type Culture Collection (ATCC). These cell lines were authenticated by the ATCC in 2012. These cell lines were maintained in RPMI media (Invitrogen) containing 10% FBS (Atlanta Biologicals), 100 U/mL penicillin, 100 mg/mL streptomycin (Invitrogen), and 2 mmol/L L-Glutamine (Invitrogen). This medium with supplements is referred to as the RF-10 medium in this article. The cultures were maintained in a humidified incubator adjusted with 5% CO 2 and 95% air atmosphere at 37
C. All cultures were split twice weekly, cell counting was conducted using a hemocytometer, and cell viability was assayed by Trypan blue staining method.
Isolation of therapy-resistant MCL cells
The therapy-resistant MCL cell lines were characterized and established after transplanting the Granta 519 into the nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice following treatment with CHOP chemotherapy and bortezomib as described previously (16, 38) . These therapy-resistant tumor cells derived from liver, kidney, and lungs were described as Granta 519 resistant from liver (GRL), Granta 519 resistant from kidney (GRK), and Granta 519 resistant from lungs (GRR), respectively, and compared with parental Granta 519 cells (GP). These cells have been shown to be resistant to chemotherapy, as confirmed both in vitro and in vivo studies. The additional properties of these therapy-resistant cell lines have been recently published (16, 38) .
The therapeutic agent In this study, we used a quinoxaline urea analogue called , which inhibits NF-kB and mTOR pathways via IKKb in pancreatic cancer cell lines in vitro and in vivo (28) . The molecular structure of 13-197 is described in Fig.  1A . The toxicity and pharmacokinetic (PK) properties of this compound have been reported by Gautam and colleagues (39) . IC 50 of in different MCL cell lines are described in Supplementary Table S1 .
In vitro growth assay
Ten thousand GP, GRL, GRK, GRR, Rec-1, and Mino MCL cells were cultured in RPMI media containing 0.5, 1.0, 5.0, 10, 20, and 50 mmol/L 13-197 or dimethyl sulfoxide (DMSO; vehicle) in 96-well plates, and the growth of these cells were determined at 24, 48, and 72 hours using MTT and 3[H]-thymidine uptake assays. Briefly, 25 mL of MTT reagent (5 mg/mL in PBS) was added to the culture and incubated for two hours before the respective time point, and the cells were lysed using an SDS-based lysing reagent. The intensity of the color developed was determined at 570 nm using a plate reader (Biotek). In another set of experiments, 0.5 mCi of 3[H]-thymidine was added 15 hours before cell harvest. The cells were harvested at 24, 48, and 72 hours using a PHD cell harvester (Cambridge Technologies). The incorporated radioactivity was counted using a liquid scintillation counter (Packard Instruments).
Apoptosis assay
The MCL cell lines were cultured at a concentration of 1 Â 10 6 cells/ml in RF-10 media containing 10 mmol/L 13-197 or DMSO for 48 hours. The percentage of cells undergoing apoptosis was then assessed using the Annexin-V:FITC apoptosis assay kit (BD Biosciences) according to the manufacturer's instructions and flow cytometry.
Cytomorphology
Control and 13-197-treated cells were washed twice with PBS. Cytospin preparations were made from different MCL cells used in this study and stained with WrightGiemsa stain in the University of Nebraska Medical Center (UNMC) pathology core laboratory, and the cytomorphology was compared by light microscopy.
Western blotting
Western blot analysis was conducted using a standardized protocol in the laboratory. Briefly, the cells were harvested after the indicated time, washed with ice-cold PBS, and lysed in a buffer containing 50 mmol/L Tris-Hcl (pH 7.0), 150 mmol/L Nacl, 0.1% SDS, 1% Na-deoxycholate, 1% NP-40, and a complete protease and phosphatase inhibitor cocktail (Pierce). For cytoyplasmic and nuclear protein extraction, a NE-PER kit (Pierce) was used according to the manufacturer's instructions. Protein concentration was determined with a protein assay kit (Bio-Rad). These protein lysates were subjected to 10% to 12% SDSpolyacrylamide gel electrophoresis. After electrophoresis and protein transfer to a polyvinylidene difluoride (PVDF) membrane, the membrane was blocked with 5% nonfat dry milk and probed with specific primary antibodies. The primary antibodies used in this study included NF-kB (p65), Mcl-1, b-actin (Santa Cruz Biotechnology), IkBa, phospho-IkBa, phospho-NF-kB (p65), Bcl-XL, S6K, phospho-S6K, 4E-BP1, phospho-4E-BP1, PARP, a-tubulin (Cell Signaling Technology), and an anti-cyclin D1 (BD Biosciences). Immunoreactivity was detected using appropriate peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology) and visualized using an enhanced chemiluminescence (ECL) detection system (Pierce, IL).
MCL patient blood samples
Primary MCL cells were obtained from four MCL patients in leukemic phase using an UNMC Institutional Review Board-approved protocol and informed consent. Peripheral blood mononuclear cells (PBMC) from patients of MCL with high lymphocyte count were isolated using a lymphocyte separation medium (Accurate Chemical and Scientific) as described previously (40) and used to evaluate the efficacy of . The immunophenotypic analysis of these cells using flow cytometry showed more than 90% CD5 and CD20 positivity. These MCL cells were treated with vehicle control (DMSO) or different concentrations of 13-197 for 24 and 48 hours to determine the efficacy of 13-197 as described earlier for the established cell lines. As an additional control, normal B cells from three healthy donors purified using Miltenyi magnetic bead separation method were used. These healthy donor samples were provided by the apheresis core unit of the UNMC clinic.
In vivo studies
All animal experiments were approved by the UNMC Institutional Animal Care and Use Committee (IACUC). For in vivo studies, six-to eight-week-old NOD.CB17-Prkdc scid /J mice were purchased from Jackson Laboratories (Bar Harbor, ME) and housed in the UNMC Comparative Medicine Animal Facilities. The NOD/SCID mice were irradiated with 215 Gy using the UNMC experimental irradiator facility. One million of therapy-resistant MCL (GRL) cells suspended in 100 mL sterile media were transplanted into NOD/SCID mice via lateral tail vein injection. After seven days, one set of seven mice was treated with cremophor (vehicle) orally and served as a control group, and another set of 10 mice was treated with 30 consecutive daily oral doses of (120 mg/kg/body weight) and served as an experimental group. When mice became moribund as evidenced by weight loss, hunching back, ruffled fur, excessive dehydration, and/or hind-limb paralysis, they were euthanized using the CO 2 chamber method. Liver, lungs, and kidneys were harvested and fixed in 10% buffered formalin solution for further histologic and immunohistologic analyses. The survival of the vehicle or 13-197-treated mice was determined by the Kaplan-Meier method and analyzed using the log rank test.
Immunohistochemistry
The H&E-stained histologic sections and immunohistochemical analyses for CD20, phospho-p65, and phospho-S6K expression of tissues harvested from control and 13-197-treated mice were conducted at the Histology Core Facility of the Nebraska Medical Center. For tumor burden analyses, the histologic sections were scanned under virtual microscopy and the tumor area was quantitated using Neuroinformatica software.
Statistical analysis
Each experiment was conducted in triplicate and repeated for an additional two to three times and the mean and standard error values were calculated. The significance of difference (P value) was calculated using independent Student t test and P values less than 0.05 were considered significant.
Results
Growth inhibitory effect of 13-197 against MCL and therapy-resistant MCL cells
As has been reported to be effective in micromolar (mmol/L) ranges of concentration to kill pancreatic cancer cells in vitro (28), we used the micromolar concentrations of Fig. S1 ), suggesting specificity to kill tumor cells only, not normal or untransformed cells.
Induction of increased apoptosis by 13-197 in MCL and therapy-resistant MCL cells
To investigate the ability of 13-197 to induce apoptosis in GP, GRL, GRK, GRR, Rec-1, and Mino MCL cells, cytomorphologic analyses and AnnexinV staining method were used in 13-197-treated cells for 48 hours. Light microscopic appearance of Wright-Giemsa stained control and treated cells are shown in Fig. 2A . Results from cytomorphology of therapy-resistant MCL cells clearly showed a significant increase in apoptotic cells in therapyresistant MCL cells treated with 13-197 compared with vehicle-only-treated control ( Fig. 2A) . To confirm this observation, Annexin-V assay was conducted where MCL cells were treated with 13-197 using the same conditions as in their cytomorphologic analyses and, then, the cells were analyzed by flow cytometry for the binding of Annexin-V to indicate induction of apoptosis. As shown in Fig. 2B , treatment with 13-197 greatly induced ($fourfold) apoptosis in all MCL cell lines compared with vehicle (DMSO)-treated cells and further confirms the ability of to induce apoptosis in these cell lines. These results are consistent with previous studies (Fig. 1) exhibiting the ability of 13-197 to inhibit proliferation and growth in malignant cells of MCL.
Downregulation of NF-kB signaling molecules in MCL cells following treatment with It has been established that NF-kB is constitutively active in malignant MCL (9) (10) (11) (12) (13) 41) . Therefore, initially, we confirmed the constitutive activation of NF-kB pathway using Western blot analysis. Our results clearly showed the increased level of nuclear NF-kB (p65) and phosphorylation of IkBa in MCL and therapy-resistant MCL cell lines as well as primary cells of a MCL patient compared with normal B cells ( Supplementary Fig. S2 ). We then explored whether 13-197 downregulates NF-kB signaling molecules in the MCL and therapy-resistant MCL cells. Initially, we examined the effect of 13-197 on IkBa phosphorylation, a major target molecule of the NF-kB signaling pathway, using Western blot method. The results indicated a significant downregulation of IkBa phosphorylation at the 5 mmol/L concentration of , and the downregulation of IkBa phosphorylation followed a dose-and time-dependent manner in MCL cell lines including the therapy-resistant cell lines examined ( Fig. 3A and C) . It is well known that phosphorylated IkBa is rapidly ubiquitinated, which leads to its proteasomal degradation, and this allows the release of NF-kB (p65) from the complex. Released p65 undergoes posttranslational modifications including phosphorylation, which leads to its nuclear translocation (25) . We next conducted Western blot analysis for NF-kB phosphorylation and nuclear translocation in DMSO-(vehicle) and 13-197-treated MCL cells following cytoplasmic and nuclear fractionation of the cells. in the therapy-resistant MCL cells. The inhibition of p65 nuclear level by was also dose dependent (Fig. 3B) . Further, our results of Western blot analysis showed decreased expression of NF-kB-regulated antiapoptotic molecules including Bcl-XL, a member of the Bcl-2 antiapoptotic gene family, overexpressed in MCL, and Mcl-1 in all 13-197-treated MCL cells (Fig. 3D and E) . Cyclin D1 is a molecule which is overexpressed in MCL and is also regulated by NF-kB (9) . We next examined the expression level of cyclin D1 by Western blot analysis following treatment of MCL cells with . As expected, the expression level of cyclin D1 was significantly decreased by at 10 mmol/L in MCL cells examined, and the decreased level of cyclin D1 followed in a dose-dependent fashion, as shown in Fig. 3F . These results were consistent with other MCL cell lines including Rec-1 and Mino (Fig. 3E) . Overall, these results suggest that 13-197 suppresses the cell growth and induced the apoptosis by abrogating NF-kB signaling pathway in MCL and therapy-resistant MCL cell lines.
13-197 inhibits the activation of mTOR pathway molecules
Constitutive activation of mTOR signaling pathway has also been implicated in the development of various malignancies including MCL (9, 19, 42) . With regard to constitutive activation of mTOR pathway in MCL, our results of Western blot analysis are also in agreement where we observed the increased phosphorylations of the mTOR downstream molecules such as S6K and 4E-BP1 in MCL cell lines, including therapy-resistant cell lines and primary cells of a patient of MCL compared with normal B cells (Supplementary Fig. S2 ). Activation of S6K and inactivation of 4E-BP1 through phosphorylation by mTOR led to increased protein synthesis, cell proliferation, and VEGF secretion and, ultimately, to tumorigenesis (26) . Because IKKb is the major upstream kinase in the NF-kB signaling pathway which is known to activate mTOR signaling pathway (27) , we examined the ability of 
Effect of 13-197 in MCL primary cells
To authenticate our previous observations in established MCL cell lines, we further investigated the antilymphoma activity of 13-197 using primary cells of patients with MCL. For this purpose, we treated MCL primary cells with increasing concentrations of . After 48 hours of treatment, cell growth and apoptosis were determined using MTT/3-H-thymidine uptake and Annexin-V assays, respectively. As shown in Fig. 5A-D nuclear NF-kB (p65) by inhibiting its nuclear translocation, and subsequently downregulated the expression level of NF-kB target molecules including Cyclin D1, Bcl-XL, and Mcl-1. Together, these results suggest that 13-197 also suppresses the cell growth and induces apoptosis by abrogating the NF-kB signaling pathway in primary cells of patients with MCL, substantiating our previous finding in established MCL cell lines.
Antitumor effect of 13-197 against therapy-resistant MCL in vivo To determine the antitumor efficacy of 13-197 against therapy-resistant MCL tumor cells in vivo, we used 17 immune-compromised NOD/SCID mice which were transplanted with GRL. We selected GRL for this study because, in a previous study, we showed that, among the stable therapy-resistant MCL cell lines we developed, GRL is the most aggressive cell line (16, 38) . Seven days after tumor transplantation, the mice were randomized and divided into two groups. One group of mice (n ¼ 7) were given vehicle (cremophor, p.o.) only, whereas another group of mice (n ¼ 10) received 13-197 (120 mg/kg/day, p.o.) for 30 consecutive days. The dose of for the treatment of mice was achieved from the reports described previously (28, 39) . The dose and schedule for 13-197 were well tolerated. On days 12 and 20 after initiation of treatment, we randomly selected three mice from each treatment group for necropsy and tumor burden analyses in different organs including liver, kidney, and lungs; this was done using CD20 immunohistochemical analyses. As shown in Fig. 6A , there was significantly decreased tumor burden in the liver, lungs, and kidney from mice treated with 13-197 compared with control. Indeed, 13-197 significantly increased disease-free survival (P < 0.001) of mice transplanted with MCL compared with control mice (Fig. 6B) , indicating that 13-197 decreases tumor burden and, thereby, increases the survival of mice. Further, we validated the 13-197 effect on targeting NF-kB and mTOR pathways in vivo. In this regard, our immunohistochemistry results with phosphorylated NF-kB (p-65) and mTOR (p-S6K) molecules showed significantly decreased levels in 13-197-treated liver, kidney, and lungs of MCLbearing NOD/SCID mice (Fig. 6C) , confirming antilymphoma efficacy targeting NF-kB and mTOR in vivo as well. Together, these results suggested that 13-197 has potential therapeutic efficacy against therapy-resistant MCL and warrants further preclinical and clinical investigations to take this approach to the clinical setting.
Discussion
In the present study, single-agent treatment of MCL with oral compound 13-197 not only suppressed cell growth and induced apoptosis in vitro, but also reduced the tumor burden and increased the survival of MCLbearing mice. In addition to the significant antilymphoma efficacy as a single agent, the 13-197 also targeted NF-kB and mTOR signaling pathways by specifically inhibiting the nuclear retention of NF-kB (p65) and phosphorylation of IkB, S6K, and 4E-BP1 in MCL cells including therapyresistant cells. Intracellular signaling pathways that control cell growth and survival mechanisms are complex, interactive, and often cross-talk with each other in various types of human hematologic malignancies. Frequently, however, these pathways including NF-kB and PI3K-mTOR are used and constitutively activated in these tumors (3, 12, 13, 19, 42) . Targeting these pathways with new and novel therapeutic agents that have molecular specificity is likely to provide improved treatment outcomes (8, 9, 43) . Novel therapies, ideally, should be based on a basic understanding of the biology of therapy-resistant MCL, especially molecular aspects of the disease progression, which translate into the clinical phenotype. Therefore, MCL cells from refractory patients needed to be evaluated, particularly tumor cells from different tissues, to understand the influence of tissue microenvironment on molecular phenotype of therapy-resistance. It is not feasible to conduct all these studies in patients with resistant MCL; therefore, to determine the efficacy and understand the molecular basis of therapy-resistance in MCL, we used the therapy-resistant MCL cell lines that we have already established from relapsed tumors from different organs of MCL-bearing NOD/SCID mice, following high-dose therapy combined with bortezomib, a proteosome inhibitor (16, 38) . These therapy-resistant cell lines served as ideal preclinical models in the present study. In this regard, targeting NF-kB and mTOR pathways in these therapy-resistant MCL cells further attest the novelty and therapeutic efficacy of .
The oral compound 13-197 showed a significant anti-MCL efficacy in our study. Recently, Radhakrishnan and colleagues (28) have shown that 13-197 has strong therapeutic efficacy against human pancreatic adenocarcinoma via targeting of the NF-kB and mTOR pathways. They have identified as an IKKb inhibitor with the screening of 13-197 against a panel of kinases. Their study shows that targets IKKb and inhibits NF-kB and mTOR signaling pathways in pancreatic cancer cell lines. With regard to toxicity and pharmacokinetics properties of Gautam and colleagues (39) have shown that does not have significant toxicity to normal tissues of mice and rats.
Our results and reports by others have shown that NFkB is constitutively expressed in refractory MCL (9) (10) (11) (12) (13) 41) . In this regard, our therapy-resistant MCL cell lines showed constitutive activation of NK-kB (p65) and IkBa. In addition, these MCL cells overexpressed Mcl-1, Bcl-XL, and cyclin D1 that are known to be regulated by NF-kB (9, 13, 14) . Treatment of MCL cells with 13-197 downregulated the constitutively active NF-kB and inhibited the phosphorylation of IkBa and p65, and ultimately suppressed the expression of proliferation (cyclin D1) and survival (Bcl-xL, Mcl-1) molecules. Cyclin D1, a NF-kBregulated gene, is overexpressed in MCL as a result of a t(11;14) chromosomal translocation, a hallmark of MCL (9) . Cyclin D1 has been previously shown to be involved in the regulation of MCL cell proliferation (9, 12) . In this article, we show that inhibition of proliferation of MCL correlated with the downregulation of the expression of cyclin D1 protein. The suppression of cyclin D1 by resulted in the suppression of MCL cell proliferation. Because NF-kB is well known to mediate antiapoptotic effects (21), we examined whether suppression of NF-kB by 13-197 could lead to apoptosis. We found that significantly induced the apoptosis in MCL cells including therapy-resistant cells and primary cells of patients with MCL that were examined (Figs. 2 and 5D ). To further elucidate the mechanism of 13-197-mediated apoptosis in MCL cells, we investigated the important apoptotic regulators, that is, Bcl-XL and Mcl-1, which are known to be regulated by NF-kB and overexpressed in MCL cells. Our results show that 13-197 downregulated the antiapoptotic genes Bcl-XL and Mcl-1 in MCL cells including therapy-resistant cells and also in MCL primary cells. Further, our data also showed that 13-197 induced the cleavage of PARP protein, a marker of apoptosis, in these MCL cells (Fig. 3B and E) . Together, the results suggest that 13-197 exerts its antiproliferative and apoptotic effects in MCL cells by inhibiting the NF-kB pathway.
IKKb, the major upstream kinase required for NF-kB activation, is constitutively phosphorylated in refractory MCL (14, 22, 44) . We found that . The histologic sections from liver, lungs, and kidney were stained with anti-CD20 antibody, imaged and quantitated, and analyzed under a digital scanner microscope using Neuroinformatica software. The images of tissue sections from different treatment groups were captured using light microscopy at Â10 magnification. B, Kaplan-Meier analyses for the survival of mice using log-rank test. Total number of mice, n ¼ 17. C, immunhistochemical analysis for the level of NF-kB (phospho-p65) and mTOR (phospho-S6K) in the liver, kidney, and lungs of MCL-bearing NOD/SCID mice following treatment with . The immunhistochemical analysis images were captured using a light microscope at Â40 magnification.
the constitutive IKKb of NF-kB pathway activation through the inhibition of IkBa phosphorylation. Inhibition of IkBa phosphorylation resulted in the suppression of constitutive phosphorylation of p65 and its nuclear translocation (Figs. 3 and 5 ). Several lines of evidence indicate that activation of IKKb leads to the activation of another downstream signaling pathway like mTOR signaling pathway molecules, that is, S6K and 4E-BP1, that increase the protein synthesis and, thereby, abnormal cell proliferation in various malignancies (20, 41, 42) . In this context, our results showed that 13-197 can perturb the mTOR signaling pathway by also inhibiting S6K and 4E-BP1 phosphorylation (Fig. 4) . These data suggest that 13-197 principally targets IKKb which leads to abrogation of NF-kB (transcriptionally) and mTOR (translationally) and, thus, suppresses cell proliferation and induces apoptosis in malignant cells of MCL.
Having shown the in vitro effect of , as a next logical step we examined the efficacy of in vivo in a mouse tumor model. NOD/SCID mice bearing therapyresistant MCL tumor showed a significant decrease in tumor burden following treatment with (Fig. 6A) . Further, this reduced tumor burden significantly reflected in increasing disease-free survival of NOD/SCID mice transplanted with MCL (Fig. 6B) , showing the ability of 13-197 as a single agent to reduce tumor burden and increase survival in an animal model. In addition, showed antilymphoma efficacy by dual targeting NFkB and mTOR pathways against therapy-resistant MCL bearing a mouse model (Fig. 6C ). In addition, we observed no significant synergistic effect in reducing tumor burden when was used in combination with CHOP chemotherapy (data not shown). This observation reaffirms that NOD/SCID mice bearing GRL tumor are already resistant to CHOP chemotherapy that we developed as a therapy-resistant model; thus, we did not observe an added effect of CHOP chemotherapy on 13-197-mediated tumor burden in mice. These findings indicate that alone has therapeutic efficacy against therapy-resistant MCL.
In summary, this is the first report evaluating the effects of a novel inhibitor 13-197 on MCL including therapyresistant MCL. The current work has shown the singleagent activity of 13-197 against MCL. Our results show that can block the constitutive activation of IKKb which perturbs NF-kB and mTOR signaling pathways, suppresses the proliferation of therapy-resistant MCL, and leads MCL cells to apoptosis through the inhibition of NFkB-regulated antiapoptotic genes in vitro. In addition, results show the antilymphoma activity of in primary cells of MCL patient samples by targeting NF-kB pathway. In addition, 13-197 alone has shown antitumor effect in reducing tumor burden and increasing diseasefree survival of NOD/SCID mice transplanted with MCL in vivo. Thus, our findings highlight the dual targeting of NF-kB and mTOR pathways by which 13-197 modulates proliferation/apoptosis and exerts its antilymphoma activity while also warranting further preclinical and clinical investigations to take this approach to clinical setting.
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